SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-057834
Filing Date
2024-05-10
Accepted
2024-05-10 16:15:42
Documents
66
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q clsd-20240331.htm   iXBRL 10-Q 996898
2 EX-10.3 clsd-ex10_3.htm EX-10.3 16614
3 EX-31.1 clsd-ex31_1.htm EX-31.1 13517
4 EX-31.2 clsd-ex31_2.htm EX-31.2 13248
5 EX-32.1 clsd-ex32_1.htm EX-32.1 8949
6 GRAPHIC img142398612_0.jpg GRAPHIC 85892
  Complete submission text file 0000950170-24-057834.txt   5634794

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT clsd-20240331.xsd EX-101.SCH 1130892
69 EXTRACTED XBRL INSTANCE DOCUMENT clsd-20240331_htm.xml XML 683596
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 678-270-3631
Clearside Biomedical, Inc. (Filer) CIK: 0001539029 (see all company filings)

IRS No.: 452437375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37783 | Film No.: 24935062
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)